2013 Publications and Awards

**Publications**


**Funding**

A pharmacogenetic trial of tacrolimus after pediatric transplantation. Mital S, Parekh RS. **SickKids Transplant Centre Catalyst Grant.** $150,000 CAD. Jan 2012 - Jan 2014

Canadian National Transplant Research Program: Increasing donation and improving transplantation outcomes. West LJ, Mital S, Parekh RS. **Canadian Institutes of Health Research.** $1,370,000 CAD. Jan 2013 - Jan 2018


CIHR MD/PhD Grant. Rosenblum ND. **Canadian Institutes of Health Research.** $660,000 CAD. Jan 2008 - Jan 2014

CIHR MD/PhD Grant. Rosenblum ND. **Canadian Institutes of Health Research.** $660,000 CAD. Jan 2009 - Jan 2015

CIHR MD/PhD Grant. Rosenblum ND. **Canadian Institutes of Health Research.** $660,000 CAD. Jan 2010 - Jan 2016

CIHR MD/PhD Grant. Rosenblum ND. **Canadian Institutes of Health Research.** $660,000 CAD. Jan 2011 – Jan 2017


CIHR MD/PhD Grant. Rosenblum ND. Canadian Institutes of Health Research. $660,000 CAD. Jan 2012 - Jan 2018

CIHR MD/PhD Grant. Rosenblum ND. Canadian Institutes of Health Research. $660,000 CAD. Jan 2013 - Jan 2019

Control of cerebellum cell specification, migration and organization by SUFU. Rosenblum ND. Canadian Institutes of Health Research. $734,120 CAD. Jun 2011 - Jun 2016

Control of complement-mediated platelet activation in aHUS via eculizumab. Licht C. Alexion Pharmaceuticals, Inc. $15,000 USD. Jan 2012 - Dec 2013

Control of kidney cell determination and morphogenesis by BMPs and beta-catenin. Rosenblum ND. Canadian Institutes of Health Research. $767,080 CAD. Jan 2008 - Sep 2013

Control of renal branching morphogenesis by hedgehog-GLI3 signaling. Rosenblum ND. The Kidney Foundation of Canada. $100,000 CAD. Jan 2012 – Jan 2014


Developmental nephrology (Tier I). Rosenblum ND. Canada Research Chairs Program. $1,400,000 CAD. Jan 2012 - Jan 2019

Discovery of Novel Targets and Development of Treatments for Complement-Mediated Disease. Licht C. 2014 Accelerator Grant in Genomic Medicine, McLaughlin Centre, University of Toronto. $30,000 CAD. 2014 - 15

Eculizumab in alport syndrome. Licht C.


The Kidney Foundation of Canada. $100,000 CAD. Jan 2012 - Dec 2013

Functions of Hedgehog-GLI-dependent signaling in stromal cells during normal and malformed mammalian kidney development. Rosenblum ND. Canadian Institutes of Health Research. $900,000 CAD. Jan 2013 - Jan 2018


Historical MPGN Cohort. Licht C. Alexion Pharmaceuticals, Inc. $28,525 USD. 2012-15


<table>
<thead>
<tr>
<th>Health Research.</th>
<th>$951,777 CAD. Jan 2013 - Jan 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary EBV infection in the immunosuppressed setting of organ transplantation: Determinants of the outcomes of virus-host interaction. Allen UD, Beyene J, Dipchand AI, Grunebaum E, Hébert D, Husain S, Mazzulli T, Ng VL, Read SE, Robinson JL, Tellier R, Weitzman SS. <strong>Canadian Institutes of Health Research.</strong> $509,125 CAD. Apr 2010 - Oct 2014</td>
<td></td>
</tr>
<tr>
<td>Regulation of leukocyte-endothelial interactions. Robinson LA. <strong>Natural Sciences and Engineering Research Council of Canada.</strong> $170,000 CAD. Jun 2012 - Jun 2017</td>
<td></td>
</tr>
<tr>
<td>The nephroprotective potential of eculizumab using COL4A3 knockout (nephrosclerotic) mice in a proof-of-concept study. Licht C. <strong>Alexion Pharmaceuticals, Inc.</strong> $65,000 CAD. Jan 2011 - Dec 2013</td>
<td></td>
</tr>
</tbody>
</table>
The Role of Slit/Robo Signaling in renal inflammation. Canada Research Chair (Tier II). Robinson LA. **Canada Research Chairs Program**. $500,000 CAD. Jul 2010 - Jun 2015